MicroRNAs (miRNAs) are small RNA molecules that can modulate gene expression to affect numerous biological processes. One such molecule, miRNA-93, is dysregulated in various diseases and might be a valuable marker of prognosis. For example, it’s generally upregulated in lung cancer, prostate cancer, glioma, osteosarcoma, and hepatocellular carcinoma, where it promotes cell proliferation, migration, and invasion to drive cancer progression. It can also induce the development of chemotherapy resistance. Furthermore, miRNA-93 contributes to coronary artery blockage, Parkinson’s disease, postmenopausal osteoporosis, and acute kidney injury. However, it’s not always upregulated in disease. In fact, it’s downregulated in gastric, bladder, cervical, and renal cancer, sometimes exerting anti-tumor effects. These differences emphasize the need to truly understand miRNA-93’s role in a specific disease before using miRNA-93 as a prognostic marker or treatment target. Nevertheless, the widespread links between miRNA-93 and ill health suggest that this miRNA is worthy of continued study to help develop new tools for disease monitoring and treatment.